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Summary
Background Compulsory supervision outside hospital has been developed internationally for the treatment of mentally 
ill people following widespread deinstitutionalisation but its eﬃ  cacy has not yet been proven. Community treatment 
orders (CTOs) for psychiatric patients became available in England and Wales in 2008. We tested whether CTOs 
reduce admissions compared with use of Section 17 leave when patients in both groups receive equivalent levels of 
clinical contact but diﬀ erent lengths of compulsory supervision.
Methods OCTET is a non-blinded, parallel-arm randomised controlled trial. We postulated that patients with a 
diagnosis of psychosis discharged from hospital on CTOs would have a lower rate of readmission over 12 months 
than those discharged on the pre-existing Section 17 leave of absence. Eligible patients were those involuntarily 
admitted to hospital with a diagnosis of psychosis, aged 18–65 years, who were deemed suitable for supervised 
outpatient care by their clinicians. Consenting patients were randomly assigned (1:1 ratio) to be discharged from 
hospital either on CTO or Section 17 leave. Randomisation used random permuted blocks with lengths of two, four, 
and six, and stratiﬁ ed for sex, schizophrenic diagnosis, and duration of illness. Research assistants, treating clinicians, 
and patients were aware of assignment to randomisation group. The primary outcome measure was whether or not 
the patient was admitted to hospital during the 12-month follow-up period, analysed with a log-binomial regression 
model adjusted for stratiﬁ cation factors. We did all analyses by intention to treat. This trial is registered, number 
ISRCTN73110773. 
Findings Of 442 patients assessed, 336 patients were randomly assigned to be discharged from hospital either on CTO 
(167 patients) or Section 17 leave (169 patients). One patient withdrew directly after randomisation and two were 
ineligible, giving a total sample of 333 patients (166 in the CTO group and 167 in the Section 17 group). At 12 months, 
despite the fact that the length of initial compulsory outpatient treatment diﬀ ered signiﬁ cantly between the two 
groups (median 183 days CTO group vs 8 days Section 17 group, p<0·001) the number of patients readmitted did not 
diﬀ er between groups (59 [36%] of 166 patients in the CTO group vs 60 [36%] of 167 patients in the Section 17 group; 
adjusted relative risk 1·0 [95% CI 0·75–1·33]). 
Interpretation In well coordinated mental health services the imposition of compulsory supervision does not reduce 
the rate of readmission of psychotic patients. We found no support in terms of any reduction in overall hospital 
admission to justify the signiﬁ cant curtailment of patients’ personal liberty.
Funding National Institute of Health Research.
Introduction
The psychiatric inpatient population has fallen drastically 
in developed countries since its peak in the mid-1950s.1 
Patients with psychosis are now routinely treated in the 
community. Many are subject to repeated compulsory 
admissions (“the revolving door syndrome”)2 and the 
absolute rate of involuntary admissions has increased.3 
Legislation for compulsory outpatient psychiatric treat-
ment has been widely introduced in the USA, Australasia, 
some Canadian provinces, the UK, and several other 
European countries.
Supervised community treatment orders (CTOs) were 
introduced in England and Wales in November, 2008.4 
This power had been sought for more than 20 years by 
some professionals5 but was resisted by a coalition of 
32 pro fessional and patient organisations.6 CTOs require 
patients to accept clinical monitoring and allow rapid 
recall for assessment but do not authorise forcible 
treatment outside hospital. The existing provision for 
“leave of absence” under Section 17 of the Act, which 
confers similar powers over outpatient care, was retained. 
This allows patients to leave hospital for some hours or 
days, or even exceptionally weeks, while still subject to 
recall. Its purpose is to assess recovery before granting 
voluntary status. The existence of this alter native made 
randomisation on discharge legally and ethically possible.7
Early opposition to CTOs focused on civil liberties8 or 
lack of improvement on the existing leave regime.9 More 
recent opposition has emphasised the absence of 
experimental evidence.10 There are several non-experi-
mental studies of CTOs10,11 but only two published 
randomised trials,12,13 both from the USA. Neither of their 
results showed a diﬀ erence in the primary outcome 
measure of readmission rates.
Results from a secondary analysis of the North Carolina 
randomised trial13 showed signiﬁ cantly fewer readmissions 
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and reduced hospital days in patients with sus tained 
CTOs (more than 180 days) and regular clinical contact 
(more than three times per month) compared with 
voluntary controls.13 CTOs in England and Wales are for 
up to 6 months in the ﬁ rst instance and renewable, and 
frequent clinical monitoring was anticipated in the 
2007 amendment.14 Our trial tests whether CTOs reduce 
admissions when patients in both groups receive equiva-
lent levels of clinical contact but diﬀ erent lengths of 
compulsory supervision. A cost-eﬀ ectiveness analysis will 
be the subject of a separate paper.
Methods
Patients and trial design
OCTET is a single-outcome randomised trial that tests 
the hypothesis that patients with a diagnosis of psychosis 
discharged from hospital on CTOs will have a lower rate 
of readmission over 12 months than will those dis-
charged on Section 17 leave. Eligible patients were 
those currently detained for inpatient treatment, aged 
18–65 years (the standard age range for UK adult mental 
health services), diagnosed with psychosis, not subject 
to any other legal restrictions, able to give informed 
consent and con sidered suitable for supervised out-
patient care by their clinical team. We report data 
obtained from medical notes and structured patient 
interviews at baseline and 12 months.
Ethical approval was granted by the Staﬀ ordshire 
National Health Service (NHS) Research Ethics Com-
mittee (reference 08/H1204/131).
Specialist mental health services in England are 
provided by area-based NHS Mental Health Trusts, each 
divided into catchment areas where community mental 
health teams (CMHTs) provided both community and 
inpatient care at the start of our trial. During recruit ment, 
many Trusts separated inpatient and community services, 
and CTOs were increasingly initiated by specialist in-
patient psychiatrists.15 Recruitment was from Nov 10, 
2008, to Feb 22, 2011. All 62 Trusts within a reason -
able travelling distance were originally approached. 
Local research governance approval was pursued with 
44 Trusts, and 32 of them, predominantly in the Midlands 
and southern England, recruited to the trial.
Randomisation and masking
Consenting participants were randomly assigned 
(ratio 1:1) by an independent statistician to be discharged 
from hospital either on CTO or Section 17 leave. Random-
isation used random permuted blocks with lengths of 
two, four, and six, and stratiﬁ ed for sex (male or female), 
Figure 1: Trial proﬁ le
*Including three patients deceased during follow-up period. †Including two patients deceased during follow-up period.
442 patients assessed for study
336 consented
322 interviewed
336 randomised
106 excluded
91 refused
6 not eligible
9 lacked capacity
14 not interviewed at baseline
10 refused
4 inadequate English
169 assigned to Section 17167 assigned to CTO
166 included in CTO group
124 as per protocol
7 not discharged
35 CTO not implemented
1 withdrew on day one
2 excluded on day one
1 already on a CTO
1 on Section 17 too long
41 not interviewed at 12 months
17 refused
10 did not attend
8 not contactable
2 inadequate English
1 team refusal
3 deceased
51 not interviewed at 12 months
26 refused
8 did not attend
12 not contactable
2 inadequate English
2 deceased
1 other reasons
125 interviewed
166 included in 
intention-to-treat analysis*
116 interviewed
167 included in 
intention-to-treat analysis†
167 included in Section 17 group
121 as per protocol
6 not discharged
40 transferred to CTO
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schizophrenic diagnosis (yes or no) and duration of 
illness (<2 years or ≥2 years).
Assignments were enclosed in sequentially num-
bered, opaque, sealed envelopes and stored by a 
researcher independent to the trial team. The details of 
the sequence remained unknown to all members of 
the trial team until recruitment, data collection, and 
analyses were com pleted. Randomisation took place 
after consent was obtained and the baseline interview 
was done. The envelope was opened on the day of the 
interview by the independent researcher after record-
ing the partici pant’s trial identiﬁ cation number on the 
envelope. She then communicated the randomised 
allo cation to the recruiting researcher by telephone.
As randomisation involved allocation to diﬀ erent legal 
statuses, it was both impossible and unlawful to mask 
research assistants, treating clinicians or patients.
Proc edures
A CTO can be imposed when the responsible clinician 
(usually a consultant psychiatrist), and an approved 
mental health practitioner (usually a social worker) deem 
that a patient needs supervision after a period of 
involuntary hospital treatment and that, without it, is 
highly likely to relapse and be readmitted involuntarily. 
The approved mental health practitioner is required to 
consult with the patient and with family carers. The 
formal process is intentionally time consuming to ensure 
it is not used for clinical convenience. Several days elapse 
between the clinical decision and CTO activation.
It can be a stipulated condition of the CTO that the 
patient takes medication outside hospital, but the CTO 
does not authorise clinicians to administer it by force. It 
allows the responsible clinician to recall the patient for 
up to 72 h to review treatment without formally readmit-
ting them. Other conditions can be imposed, such as 
place of residence and attendance at regular assessments. 
All conditions must be speciﬁ ed in the CTO documents. 
A CTO initially lasts up to 6 months, renewable for a 
further 6 months, and subsequently for 1-year terms. It 
can be discharged at any time by the responsible clinician 
or by a mental health tribunal if the patient’s mental state 
or circumstances improve. During the CTO period, the 
hospital treatment order (Section 3) remains in place but 
is inactive; it is reactivated if the CTO is revoked after a 
recall to hospital.
Section 17 leave is a well established rehabilitation 
practice, used for brief periods to assess the stability of a 
patient’s recovery after or during a period of involuntary 
hospital treatment. The treatment order (Section 3) 
remains active and the patient can be immediately 
readmitted without additional legal processes. Medica-
tion cannot be given by force in the community. Section 
17 leave is extensively used but, as a continuation of 
Section 3, no routine data are collated. Its frequency and 
duration are therefore unknown but both are believed to 
be highly variable. Patients can be discharged directly 
from Section 3 without the need for either Section 17 
leave or a CTO, and most are. Such patients would not be 
eligible for recruitment to this trial.
Our trial thus randomly assigned patients to two forms of 
mandatory outpatient care. A legal opinion on the trial 
concluded that, although there are undoubtedly diﬀ erences 
between the CTO and leave regimes, an area of genuine 
legal equipoise exists; it is unclear whether either regime is 
more restrictive than the other and it is possible for a 
patient simultaneously to meet the criteria for both.7
Statistical analysis
The primary, binary outcome measure was whether or 
not the patient was admitted to hospital during the 
12-month follow-up period. Secondary hypotheses were 
that CTOs would prolong time to ﬁ rst readmission, 
reduce the number of admissions and overall time in 
hospital, and improve clinical and social functioning. The 
secondary hospitalisation outcome measures were time 
to ﬁ rst readmission, number of days in hospital, and 
number of readmissions during follow-up. We assessed 
clinical outcome using the Brief Psychiatric Rating Scale 
Missing data 
(n=336)
CTO
(n=167)
Section 17 
(n=169)
Demographics
Age (years) 0 (0%) 39·8 (11·2) 39·5 (11·7)
Male sex 0 (0%) 111 (66%) 114 (67%)
Years of education 4 (1%) 11·8 (1·7) 12·0 (2·1)
Ethnic origin 0 (0%)
White ·· 102 (61%) 104 (62%)
Black ·· 38 (23%) 40 (24%)
Asian ·· 15 (9%) 14 (8%)
Mixed and other ·· 12 (7%) 11 (7%)
Born in UK 1 (<1%) 135 (81%) 124 (74%)
Living situation
Married or cohabiting 2 (<1%) 11 (7%) 18 (11%)
Identiﬁ ed carer 30 (9%) 62 (41%) 50 (32%)
Independent accommodation 2 (<1%) 118 (71%) 123 (73%)
Living alone or homeless 18 (5%) 123 (79%) 116 (72%)
Clinical status
Schizophrenia 0 (0%) 141 (84%) 145 (86%)
BPRS 22 (7%) 38 (30–48) 38 (32–49)
GAF 25 (7%) 38·3 (9·4) 39·3 (10·2)
Clinical history
Duration of illness (years) 9 (3%) 12 (6–20) 12·5 (5–21)
Less than 2 years illness duration 0 (0%) 7 (4%) 7 (4%)
Number of past psychiatric hospital admissions 22 (7%) 6 (3–8) 5 (3–9)
Duration of past psychiatric hospital admissions (months) 58 (17%) 14 (6–28) 15 (7–30)
Number of past involuntary hospital admissions 33 (10%) 4 (2–7) 3 (2–8)
Criminal conviction 31 (9%) 65 (43%) 68 (44%)
Previous imprisonment 24 (7%) 41 (27%) 45 (28%)
Data are number (%), mean (SD), or median (IQR). CTO=community treatment orders. BPRS=brief psychiatric rating 
scale. GAF=global assessment of functioning.
Table 1: Patient characteristics at baseline
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(BPRS), a well established scale rating 24 symptoms from 
1 (absent) to 7 (extremely severe).16 We assessed social 
outcome using the Global Assessment of Functioning 
(GAF), which gives a single score between 1 (for a severe 
life threatening state) to 100 (for superior functioning).17 
The scale has clearly anchored deciles and established 
reliability. We used both scales at baseline and 12 months, 
administered by independent, trained researchers.
A sample size of 288 patients was needed to detect a 
diﬀ erence of 16% in the proportion readmitted to a 
psychiatric hospital between the two groups (48% in 
section 17 vs 32% on CTO) as in the North Carolina trial,13 
assuming α of 5% and power of 80%. We predicted 
attrition to be negligible as primary outcome data were 
available from medical records.
Two interim analyses, prepared by an independent statis-
tician, and masked to the investigators, were sub mitted to 
an independent data monitoring committee who agreed 
unanimously that it was safe to continue the trial.
The trial team wrote and signed oﬀ  a detailed statistical 
analytical plan before any data were analysed. All analyses 
were done according to the analysis plan.
We analysed the primary outcome using a log-binomial 
regression model adjusted for stratiﬁ cation factors (sex, 
schizophrenic status, and duration of illness). The result 
is presented as an adjusted relative risk with 95% CI. We 
analysed count outcomes such as number of nights in 
psychiatric hospital admission and number of readmis-
sions using adjusted negative-binomial or zero-inﬂ ated 
Poisson regression models dependent on data distri bu-
tion. We present the results as adjusted incident-density 
ratios (IDR) with 95% CIs and interpret them in a similar 
way as relative risks.
We analysed time-to-event outcomes such as time 
from randomisation to readmission using proportional 
hazards regression models and present the results as 
adjusted hazard ratios (HRs) with 95% CIs along with 
Figure 2: Time to readmission
CTO=community treatment orders.
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Figure 3: Duration of admissions in months
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CTO (n=166) Section 17 (n=167) Treatment eﬀ ect
N Number (%) or 
mean (SD)
Median (IQR) N Number (%) or 
mean (SD)
Median (IQR)
Primary outcome
Psychiatric hospital readmission 166 59 (36%) ·· 167 60 (36%) ·· 1·00 (0·75 to 1·33)*
Secondary outcomes
Total duration of all psychiatric 
hospitalisations (nights)
166 82·2 (102·0) 41·5 (8–109) 167 90·9 (104·5) 48 (10–133) 0·90 (0·65 to 1·26)†
Number of readmissions 59 1·2 (0·6) 1 (1–1) 60 1·4 (0·8) 1 (1–2) 0·82 (0·58 to 1·16)†
Number with multiple readmissions 166 10 (6·0%) ·· 167 18 (10·8%) ·· ··
Days in community until ﬁ rst readmission 166 246 (122·4) 295 (140–357) 167 241 (126·5) 292 (126–354) p=0·755‡
Clinical outcomes
BPRS (at 12 months) 122 38·2 (11·5) 35 (29–44) 112 38·3 (12·4) 34 (30–43·5) −1·09 (−3·25 to 1·07)§
GAF (at 12 months) 123 39·0 (12·0) 36 (31–45) 114 39·7 (13·1) 35·5 (30–45) −0·86 (−2·93 to 1·20)§
CTO=community treatment orders. BPRS=brief psychiatric rating scale. GAF=global assessment of functioning. *Relative risk (95% CI). †Incident density ratio (95% CI). 
‡Wilcoxon rank-sum p value. §Adjusted mean diﬀ erence (95% CI) from linear mixed eﬀ ects model.
Table 2: Outcomes at 12-month follow up
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Kaplan-Meier plots. We compared other outcomes with 
distributions that violated assumptions for all the above 
methods using Wilcoxon rank-sum tests.
We used mean imputation to calculate BPRS total 
score for cases with at least ten items completed. For 
BPRS and GAF, we estimated treatment eﬀ ect and 
change over time using a hierarchical model with 
random patient intercept adjusting for stratiﬁ cation 
factors. We did all analyses according to the intention-to-
treat principle. We performed sensitivity analyses, which 
were unadjusted for stratiﬁ cation factors. We used Stata 
version 12.1 for all analyses. This trial is registered, 
number ISRCTN73110773.
Role of the funding source
The views expressed in this presentation are those of the 
authors and not necessarily those of the NHS, the NIHR, 
or the Department of Health. The sponsor of the trial 
had no role in trial design, data collection, data analysis, 
interpretation, or writing of the report. The corres-
ponding author had full access to all the data in the trial 
and had ﬁ nal responsibility for the decision to submit 
for publication.
Results
Of 442 patients assessed by the study team, 336 patients 
were randomly assigned to receive either CTO 
(167 patients) or Section 17 (169 patients; ﬁ gure 1). Table 1 
shows baseline characteristics. One patient withdrew 
and two were identiﬁ ed as ineligible directly after ran-
domisation (ﬁ gure 1). Data for the primary outcome 
measure were available from medical records for all 
333 patients. 241 (72%) patients were interviewed at 
12 months and baseline characteristics did not diﬀ er 
between those who were interviewed and those who were 
not (appendix p 1). Five people died during follow-up: 
two deaths by suicide, and one by accidental death from a 
drug overdose were recorded in the CTO group, and one 
death by suicide and one death from natural causes were 
recorded in the Section 17 leave group.
Primary, secondary, or clinical outcomes did not diﬀ er 
between groups (table 2). At 12 months, neither the 
number of patients readmitted, nor the time to readmission 
from randomisation, nor the number of days in hospital 
diﬀ ered (table 2; ﬁ gure 2). The pattern of duration of 
individual admissions seemed similar for both groups 
(ﬁ gure 3). Neither symptoms as measured by BPRS nor 
social functioning as measured by GAF diﬀ ered between 
groups at 12 months (table 2). A sensitivity analysis 
excluding those who did not receive CTO and those who 
went directly from Section 17 to CTO gave similar results.
The duration of time in the community after hospital 
discharge under initial randomised compulsory out patient 
supervision (ie, randomised compulsion) was substantially 
longer in the CTO group (table 3); as was the time to ﬁ rst 
voluntary status (appendix p 2). Time from randomisation 
to discharge from hospital was similar between groups 
(median 8 days in the CTO group vs 16 days in the Section 
17 group, HR 1·08 (95% CI 0·86–1·34; appendix pp 3–4). 
Overall, the total number of days under compulsion 
during follow-up was signiﬁ cantly greater in the CTO 
group (median 255 days) than in the Section 17 group 
(102 days; p<0·0001). This total number of days included 
compulsion under the randomised regime (either CTO or 
Section 17), any time on CTOs for crossover patients in 
the Section 17 group, and any time on a subsequent CTO 
or Section 17 for patients who came under these regimes 
more than once during follow-up. Self-reported monthly 
rate of clinical contacts during the time outside hospital 
did not diﬀ er between the two groups (table 3).
Discussion
Our results do not support our hypothesis. Despite a 
more than three-fold increase in time under initial 
supervised community care, the rate of readmis sion to 
hospital was not decreased by CTOs. Neither was the 
time to readmission decreased nor was there any 
signiﬁ cant diﬀ erence in the number or duration of 
hospital admissions. We also recorded no diﬀ erences in 
clinical or social outcomes.
We chose the rate of readmission as our primary out-
come, and powered our trial on it, because CTOs have 
been legislated explicitly for this outcome, and it is 
also the primary outcome in most major studies,10,11,18 
including the only two published randomised trials 
(panel).12,13 The total number of days in psychiatric 
hospital was very similar for both groups in our trial, as 
was the time from randomisation to initial discharge. 
Several patients remained in hospital for most of the trial 
period, including 13 who were never discharged, because 
of deteriorations of their clinical state, and who had no 
opportunity to be supervised in the community. Patterns 
See Online for appendix
CTO (n=166) Section 17 (n=167) Treatment eﬀ ect
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Days under any legal compulsion during follow-up 241·4 (121·1) 255 (148–365) 134·6 (114·1) 102 (31–212) p<0·0001*
Days in community under randomised legal compulsion 170·1 (134·4) 183 (0–299) 45·5 (80·7) 8 (0–37) p<0·0001*
Number of contacts with service (per month) 3·0 (3·1) 2·1 (0·8–4·4) 3·9 (5·9) 2·2 (0·8–4·7) 0·77 (0·47–1·26)†
Data are mean (SD) or median (IQR). *Wilcoxon rank-sum p value. †Incident density ratio (95% CI).
Table 3: Treatment process
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of care will be carefully examined in subsequent health 
economic analyses.
The number of protocol violations is noteworthy 
(42 violations in the CTO group and 46 in the Section 17 
group). Three factors contributed to this result. First, 
the legal position underpinning the lawfulness of the 
trial required each subsequent clinical decision to be 
entirely unconstrained by the randomisation.7 Conse-
quently, clinicians could not be encouraged to persist 
with the initial randomised assignment. Second, recruit-
ment of patients was at the point that the clinical team 
decided to initiate supervised outpatient care. Finalisation 
of a CTO requires detailed consultation both within the 
team and with the patient and their family, which can 
take from a few days to several weeks. Third, adherence 
to randomisation was compromised by reorganisation in 
almost all of the collaborating mental health services, 
particularly by the separation of inpatient and outpatient 
consultant responsibility. As a result, many patients 
passed to being treated by psychia trists unfamiliar with 
the trial and who might have had diﬀ erent opinions 
about management. A sensitivity analysis removing 
these protocol violations did not alter our ﬁ ndings.
A limitation of testing the impact of a new intervention 
at its outset is a possible slow acquisition of conﬁ dence 
and skills in its use, thereby reducing trial generalisability. 
The median duration of the initial CTOs in our trial was 
6 months, indicating that about half were being renewed. 
Combined with clinical contacts averaging over two per 
month, this result suggests that CTOs are being imple-
mented in line with the legislators’ expectations.
Figures for the average duration of CTOs in England and 
Wales are not available. Centrally obtained data are diﬃ  cult 
to interpret but seem broadly in line with the pattern 
observed in our trial. Of the 14 295 CTOs issued from 
2008–12, 3922 have been discharged, 3409 revoked, and 
4764 reported to be in place at the end of 2012. For each of 
the last 3 years, about 4000 new CTOs have been issued, 
with between 2000 and 3000 revoked or dis charged, the 
remainder presumably being renewed or allowed to lapse 
as patients are judged to need them no longer.19
Only patients deemed suitable for a CTO were eligible 
for our trial, and many patients were discharged from 
Section 3 with a period of Section 17 without being 
included. The legal requirements for the trial restricted 
eligible patients to those deemed “suitable for dis-
charge either to Section 17 leave or CTO”. Collaborating 
clinicians accepted that in the absence of convincing 
evidence of eﬃ  cacy, any patient they deemed suitable for 
CTO was also eligible for leave. Those who believed 
otherwise (or were committed to a routine use of 
protracted Section 17 leave as an alternative) did not 
recruit to the trial. It was not possible to obtain 
information about those patients on whom collaborating 
clinicians imposed CTOs without entering them into the 
trial. This certainly did happen on several occasions, 
especially when patients’ families had expressed strong 
preferences. The exclusion of obvious candidates for 
CTO could potentially bias against proving an eﬀ ect of 
CTOs, but this bias is impossible to estimate.
This is the third, and largest, randomised trial of CTOs, 
and, similar to its predecessors, did not ﬁ nd any evidence 
that CTOs achieve their intended purpose of reducing 
readmission in so-called revolving door pa tients with a 
diagnosis of psychosis. The evidence is now strong that 
the use of CTOs does not confer early patient beneﬁ ts 
despite substantial curtailment of individual freedoms. In 
view of the now consistent experimental evidence against 
any clear beneﬁ t, we believe any proposal to either 
introduce CTOs to new jurisdictions or extend their use 
would require a commitment to test their eﬀ ects at least 
as rigorously as we have done. Major ethical and legal 
barriers have to be overcome to do such research.7,20,21 
International experience indicates that clinicians rapidly 
form strong opinions for or against CTOs and clinical 
equipoise is soon lost.22 However, as previously argued, 
the introduction of such restrictions on patient liberties 
would be unethical unless accom panied by a rigorous 
assessment of their potential costs and beneﬁ ts.23
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Panel: Research in context
Systematic review
Two detailed reviews10,11 have been published of research into 
community treatment orders (CTOs) covering more than 70, 
mainly observational, studies and local clinical assessments. 
Only two randomised trials have been published12,13 and 
neither found any clear advantage to CTOs in terms of 
reducing hospital admission in patients with a diagnosis of 
psychosis. Both randomised trials are more than a decade old 
and were done in the USA. Since then, CTOs have been 
introduced in several European countries including England 
and Wales in 2008.
Interpretation
Results from our trial showed no diﬀ erence in the proportion 
of patients readmitted to hospital between study groups, nor 
in the time to readmission over a 1-year follow-up. The 
overall duration of hospital care did not decrease nor did 
clinical or social functioning improve despite an average of 
6 months additional compulsion. These ﬁ ndings conﬁ rm 
previous evidence that CTOs do not confer beneﬁ ts on 
patients with a diagnosis of psychosis, and their current high 
usage should be urgently reviewed.
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